MedTrace Logo

Efficacy and Safety ofSanGrow Decoction for Patients With Diabetes

NCT02660593 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2016-04-27

No results posted yet for this study

Summary

MedlinePlus related topics: Blood Sugar

Primary Outcome Measures:

* Fast glucose and HbA1c change between the baseline and end of study \[ Time Frame: From baseline to 30 and 100 days\]
* \[ Designated as safety issue: No \]
* Successful rate of blood glucose control (the proportion of patients with HbA1c \<7%) \[ Time Frame: From baseline to 30 days and 100 days\] \[ Designated as safety issue: No \]

Secondary Outcome Measures:

• To evaluate the change of quality of life in the 1 months by the health questionnaire SF-36 \[ Time Frame: From baseline to month 1 \] \[ Designated as safety issue: No \]

Conditions

Interventions

DIETARY_SUPPLEMENT

SanGrow Decoction

SanGrow Decoction is perpared according to the principle of Chinese medicine to treat thirsty and maransis.

Sponsors & Collaborators

  • Shidaihuajing Institute for Diabetic Research

    lead OTHER

Principal Investigators

  • Shizhan CHi, PhD · Shidaihuajing Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
10 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2017-03-31
Completion
2017-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02660593 on ClinicalTrials.gov